key: cord-1023202-67ts7ivd authors: Usman, Asad; Gutsche, Jacob title: Essential Topics in the Management of Venovenous Extracorporeal Membrane Oxygenation in COVID-19 Acute Respiratory Distress Syndrome date: 2021-05-08 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2021.04.044 sha: e8ee14a2d10278e2d98d3374d67bd164b7cd4daa doc_id: 1023202 cord_uid: 67ts7ivd nan For over a year, patients around the world have suffered the effects of COVID-19 infection including acute respiratory distress syndrome (ARDS). Most patients with COVID-19 infection remain asymptomatic, however approximately 5-20% of patients develop severe ARDS requiring admission to the intensive care unit and mechanical ventilation. [1] [2] [3] Strategies to manage this subset of patients include low stretch mechanical ventilation, prone positioning, and neuromuscular blockade. 4 When these strategies fail due to refractory hypoxemia, severe hypercarbia, or requirement for severely injurious MV settings; venovenous extracorporeal membrane oxygenation (VV ECMO) can be an option. VV ECMO allows lung rest ventilator settings, may permit safely waking the patient up to start physical therapy, and give the patient time as a bridge to recovery or lung transplantation. 5 Management of mechanical circulatory support in COVID-19 ARDS requires a highly resourced multidisciplinary ICU team and the ability to nimbly develop protocols for care for this new patient population. Here we discuss some unique aspects of care using VV ECMO management in COVID-19 ARDS. Early observation on the phenotypic expression of severe COVID-19 ARDS have demonstrated a spectrum between two variants: one with normal static lung compliance with refractory hypoxemia and the second with reduced lung compliance with hypoxemia. 6 In the high compliance group, higher positive end expiratory pressure (PEEP) levels may cause harm by compromising hemodynamics and cardiovascular performance without an improvement in oxygenation. In the low compliance group, patients have stiff lungs that sometimes require injurious levels of MV to achieve oxygenation or carbon dioxide removal. These observations suggest that there is a spectrum of COVID-19 lung injury and mechanical ventilation management should be individualized. This is particularly salient for when considering VV ECMO as a salvage therapy. After instituting VV ECMO clinicians can rest the lung by reducing positive end expiratory pressure and tidal volume size. Low stretch ventilation is the standard of care for ARDS as well including judicious PEEP and tidal volumes in the 4-6 mL/kg range. 7 We are occasionally asked to consider patients for VV ECMO prior to avoid intubation. Early VV ECMO in COVID-19 infection is a possible but there are no prognostic criteria or scoring systems which can predict the likely trajectory of a COVID-19 infection. Some patients will develop severe ARDS while others may recover with a short course of MV. At this time, only one published case report of pre-emptive ECMO cannulation prior to MV exists, and with the current intracranial hemorrhage rate associated with VV ECMO in COVID patients, it would be hard to justify this as a standard practice. 8 Patients after cannulation should be kept sedated and paralyzed for the first 7 to 10 days with relatively high mean airway pressure, while the minute ventilation is reduced. During this phase, any attempt at spontaneous breathing may be effective at promoting gas exchange, but often generates very large tidal volumes, and in our practice appears to be accelerating lung injury. This is called patient self-induced lung injury (P-SILI). 9 Subsequently, after an initial period of deep sedation and paralysis, the neuromuscular blocking drugs (NMBD) can be weaned. This initial period of sedation/paralysis may be utilized for a trial of proning, which we are now performing on all COVID ARDS VV ECMO patients. 10, 11 After an initial period of complete paralysis, partial neuromuscular blockade targeting ¾ or greater twitches can help bridge injured lung back to spontaneous ventilation. Low dose NMBD infusions can be used to decrease accessory muscle activation to limit tidal volumes while allowing the diaphragm to contract. This approach is controversial due to patients feeling awake while experiencing mild to moderate weakness. Multiple centers have used this strategy with success. 12, 13 Low dose paralysis patients usually require low dose sedation and reassurance. Sedation can be achieved through a mixture of ketamine, lidocaine, propofol, as well as dexmedetomidine. Longer acting medications such as methadone, quetiapine, and diazepam can also be used to create a steady state of sedation and anxiolysis while on VV ECMO. The goal of this strategy is to titrate tidal volumes below 4 -6 cc/kg, even during spontaneous ventilation modes so that the patient does not injure their lungs with high negative pressures. The patient will still be able to move and trigger inspiration cycles, but their breathing and potentially coughing will not be as strong. The second phase of lung management should include ventilating patients with spontaneous modes. This includes pressure support (PSV) or neurally adjusted ventilation adjusted (NAVA) while maintaining low stretch low tidal volumes. 14 This spontaneous patient driven effort allows for the preservation of diaphragm function. Spontaneous ventilation may reduce ventilator desynchrony and therefore reduce sedation requirements. The team should have a strategy to deal with hypoxia. Maintenance of diaphragm function as well as routine neurological assessment with decreased sedation are critical due to the high risk of intracranial hemorrhage or if transplantation is considered. 15 Finally, we have found a high incidence of pneumothorax in late fibrotic COVID ARDS lungs. The extreme lung damage found in COVID ARDS can lead to pneumothorax as well as trapped lung. At our institution, in 1632 patients admitted to the ICU with COVID-19, 137 chest tubes were placed, and 92 (5.2%) were for pneumothorax. Chest tube placement for patients on VV ECMO because invasive procedures are often associated with bleeding. Initial management should be focused on using ECMO support to limit VILI and combat hypoxemia. Lung injury is proportional to the mechanical power applied to the lung which takes into effect the tidal volume, driving pressure, respiratory rate, and inflation/deflation cycles, as well as the PEEP. We suggest weaning FiO2 on the ventilator as well as PEEP support while keeping ECMO flows approximately two times greater than body surface area. Once, patients have achieved steady state on the ventilator, ECMO weaning should commence. Recently we have encountered patients with persistent hypercarbia despite a minimal oxygen requirement. Several authors have suggested calculating CO2 production based on metabolic and respiratory mechanics to predict successful weaning from sweep gas flow. 16, 17 To ensure suitability for decannulation, extended sweep off trials for some patients are necessary in the final stage of weaning VV ECMO. Many patients suffering from COVID ARDS retain carbon dioxide, despite optimal ventilator settings. Minimal sweep on the ECMO circuit (0.5 liters sweep) has not been able to assure us that patients are ready for decannulation, and some patients have been recannulated despite tolerating minimal settings. One concern for sweep off trials is the concern for plasma leak, which was a problem in older oxygenators. We have performed multiple sweep off trials with Quadrox oxygenators without circuit clotting or failure events. Personal communication with Gentinge, the Quadrox oxygenator manufacturer, assures us that they are not aware of any problems with this practice. In addition, we have reached out to other major centers, who confirm using sweep off trials safely. Importantly, with the sweep off, no oxygen is being delivered to the circuit, so patients should be on minimal oxygen settings (< or =0.3 FIO2) prior to a sweep off trial. Finally, bridge to hemolung, extracorporeal carbon dioxide removal (ECCO2R), is feasible to allow for a smooth transition. We have used the hemolung in multiple patients to safely bridge off ECMO and allow the patient to continue spontaneously ventilating and participating in physical therapy. Several factors related to ECMO contribute to coagulopathy including, dilutional effects of the extracorporeal circuit, consumption of factors exposed to foreign surfaces, altered platelet surface protein function, hyperfibrinolysis, and acquired von Willebrand syndrome. 18, 19 Recently, Rivosecchi These patients are at high risk for intracranial hemorrhage (ICH) due to numerous factors, including labile blood pressure, which is seen in most of these patients. 15, 24 Exposure to the ECMO tubing, oxygenator, and pump cause variable pharmacodynamics of opioid medications. The PVC tubing and PMP oxygenator surfaces absorb lipophilic narcotic agents. Furthermore, after circuit exchanges or oxygenator exchanges there might be wide fluctuation in sedation and awareness. Circuit changes events may also cause dynamic blood pressures changes. These are critical moments where the clinician should be closely involved. We try to control blood pressure and keep patients on a regimen of enteral labetalol and hydralazine. However, if patients are concurrently on vasopressor medications for sepsis or inotropic medications, such as epinephrine, to augment RV function there might be variable GI absorption of these medications. With intravenous hydralazine on shortage, alternative antihypertensives such as clonidine, propranolol might be needed as well as using sedatives as antihypertensives. Sedation with dexmedetomidine may help as well. We titrate our antihypertensives to a goal systolic blood pressure should be below 160 mmHg if possible. Cautiously consider early surgical tracheostomy to facilitate weaning paralytics and/or sedation. Clinicians need to balance the benefits against the elevated risk of bleeding with tracheostomy on ECMO. Sedation management can be challenging in COVID-19 ECMO patients. Awake ECMO is a possibility with COVID ARDS however this needs to be balanced with the disease arc (early versus late, compliant versus fibrotic) as well as patient specific factors. All patients with CARDS are placed on ECMO with the intention as a bridge to recovery, however in a subset of patients they may need to bridge to transplantation. Therefore, awake VV ECMO allows for participation with physical therapy and decreases the risk for skin breakdown and muscle wasting. It is not uncommon to find extremely high doses of intravenous opioid infusions, benzodiazepine infusions, and propofol infusions; however, clear daily sedation weaning plans must be made to decrease the burden over days to weeks. Transition to longer acting agents is ideal. Methylphenidate and quetiapine can be added to aid in neurocognition and wakefulness in extreme circumstances. Persistent and refractory coughing is a common problem in the COVID ARDS population. Causes of coughing can be due to mechanical irritation as well as dysregulation of neuropulmonary stretch receptors. Severe pulmonary consolidation of the lungs can also cause air hunger and subjective sensation of suffocation. General strategies for cough suppression due to mechanical irritation include matching the appropriate tracheostomy tube to the airway. Essential aspects of tracheostomy design include variable cuff profiles such as foam cuffs, air cuffs, hi/lo cuffs, and cuffless designs. There is also variability in the horizontal and distal lengths as well as curvature. Finally, tracheostomy tubes can be constructed with wire reinforcement or PVC both flexible and rigid. Having a wide range of options to fit each particular patient's tracheostomy may help limit direct stimulation. For patients on VV ECMO ventilator weaning while on ECMO is possible as long as they are able to tolerate the tracheostomy. Any plans for awake VV ECMO need to include appropriate strategies to mitigate coughing. Otherwise, ambulatory and awake VV ECMO will be difficult due to rapid changes in ECMO flows due to the coughing. Lidocaine infusions and nebulization can be used to address coughing as well as guaifenesin and codeine. Low dose ketamine infusions can help suppress coughing and by bronchodilation; however, ketamine may increase secretions. The team should have as needed rescue medications ordered to treat refractory episodes of coughing. Finally, soft suctioning catheters, such as red rubber catheters, may be used to prevent exacerbation of airway injury during suctioning. A secondary issue occurs with prone positioning on VV ECMO after tracheostomy. Proning with a tracheostomy presents a logistical challenge and safety concern including loss of airway protection, kinking of the tracheostomy tube, as well as direct pressure injury to the anterior neck. If patients on VV ECMO with tracheostomy require proning then elective orotracheal intubation with temporary stoma closure may be considered. Several challenges exist with the management of VV ECMO in COVID ARDS. Early institution of VV ECMO prior to mechanical ventilation is possible but has not become commonplace. After cannulation, the ventilator should be weaned and deep paralysis used to prevent lung injury and P-SILI. Partial paralysis can help transition off VV ECMO. ECCO2R is a tool that can be used to bridge patients with prolonged carbon dioxide retention after COVID ARDS. Bivalirudin is an alternative, potentially better, anticoagulation medication than unfractionated heparin. Sedation management should include long-acting agents as well as non-traditional medications such as lidocaine, ketamine, methadone, and dexmedetomidine. All these insights are not gospel, but rather emanate from a year-long effort to manage the sickest of the sick COVID ARDS patients. Coronavirus Disease 2019 (COVID-19) in Italy The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine Respiratory Mechanics and Gas Exchange in COVID-19-associated Respiratory Failure Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. The Lancet Respiratory Medicine Management of COVID-19 Respiratory Distress PEEP levels in COVID-19 pneumonia Early Usage of Extracorporeal Membrane Oxygenation in the Absence of Invasive Mechanical Ventilation to Treat COVID-19-related Hypoxemic Respiratory Failure A physiological approach to understand the role of respiratory effort in the progression of lung injury in SARS-CoV-2 infection Prone Positioning during Venovenous Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome Multicenter Cohort Study and Propensity-matched Analysis Prone Positioning in Severe Acute Respiratory Distress Syndrome Partial Neuromuscular Blockade during Partial Ventilatory Support in Sedated Patients with High Tidal Volumes. American journal of respiratory and critical care medicine Adaptive periodic paralysis allows weaning deep sedation overcoming the drowning syndrome in ECMO patients bridged for lung transplantation: A case series Spontaneous Breathing during Extracorporeal Membrane Oxygenation in Acute Respiratory Failure A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19 Extracorporeal gas exchange: when to start and how to end? Critical care How I wean patients from veno-venous extra-corporeal membrane oxygenation Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation Factors associated with hemolysis during extracorporeal membrane oxygenation (ECMO)-Comparison of VA-versus VV ECMO Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin. Critical care medicine Thrombosis and Coagulopathy in COVID-19 Patients Requiring Extracorporeal Membrane Oxygenation Increased Intracranial Hemorrhage Amid Elevated Inflammatory Markers in those with COVID-19 Supported with Extracorporeal Membrane Oxygenation Association of inflammatory markers with the severity of COVID-19: A meta-analysis A Double-Edged Sword: Neurologic Complications and Mortality in Extracorporeal Membrane Oxygenation Therapy for COVID-19-Related Severe Acute Respiratory Distress Syndrome at a Tertiary Care Center The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.